Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Subcutaneous Drug Delivery Market – Market Insights
Subcutaneous drug delivery route has emerged as a promising and viable alternative to intravenous administration. The demand for subcutaneous delivery route is attributed to the rapid development of biologics in fastest growing sector of the pharmaceutical industry. Moreover, the subcutaneous route of administration is generally preferred, as it enables self-medication, improves quality of life, and thus reduce health care costs.
Furthermore, convenience and safety for both patients and medical professionals offered by subcutaneous devices are major factors leading to growth of the global subcutaneous drug delivery market. According to World Health Organization, 2014, around 2 million healthcare professionals suffered from infectious diseases as result of needlestick injuries globally. The retractable nature of prefilled syringes help to overcome this problem acting as an ideal device to reduce the occurrence of needlestick injuries.
The global subcutaneous drug delivery market size was valued at US$ 7,077.5 million in 2017 and is expected to exhibit a CAGR of 9.5% over the forecast period (2018–2026).
Figure 1. Global Subcutaneous Drug Delivery Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of arthritis, multiple sclerosis, and diabetes to propel the global subcutaneous drug delivery market growth.
Increasing prevalence of multiple sclerosis (MS), rheumatoid arthritis, diabetes, and food allergies is expected to drive growth of the global subcutaneous drug delivery market, as most of the drugs are administered through subcutaneous drug delivery route. According to the study by National Multiple Sclerosis Society, 2017, an estimated 1 million people in the U.S. are living with MS, where around 200 new cases are diagnosed each week in the U.S.
According to the Multiple Sclerosis Trust, 2018, an estimated 2,500,000 people in the world have multiple sclerosis. According to the Arthritis Foundation, 2017, around 41 people were diagnosed with Rheumatoid arthritis (RA) out of every 100,000 people in the U.S. The foundation further states that about 1.3 million Americans have RA.
According to the Indian Diabetes Research Foundation, 2016, around 60% of the world’s population suffering from diabetes lives in Asia, with around one-half in China and India combined. The foundation also states that Western Pacific reported over 138.2 million people suffering from diabetes in 2015, the number for which is expected to rise to 201.8 million by 2035.
According to the World Health Organization (WHO), around 200 to 250 million people suffered from food allergies worldwide in 2015. Moreover, according to the European Academy of Allergy and Clinical Immunology (EAACI), in 2015, around 17 million people suffered from food allergies in the U.K., of which around 3.5 million were children.
However, the unavailability of approved products due to increasing number of product recalls by various developers is a factor hindering growth of the global subcutaneous drug delivery market. In 2015, Sanofi US voluntarily recalled Auvi-Q (epinephrine injection, USP) including both 0.15 mg and 0.3 mg strengths from hospitals, retailers, and consumers, as the products had inaccurate dosage delivery, resulting in failure to provide intended drug dose.
Figure 2. Global Subcutaneous Drug Delivery Market Share (%), by Disease Indication
Source: Coherent Market Insights Analysis (2019)
Prevention of needlestick injuries to bolster the market growth.
Increasing awareness regarding safety and concern of needlestick injuries is a major factor driving growth of the global subcutaneous drug delivery market. According to the Health Protection Agency (HPA) report, in 2012, injuries among medical and dental professionals while treating patients increased by 131% (100-231) from 2002 to 2011.
Moreover, preference for safety injection devices is increasing among healthcare professionals and manufacturers, as these devices decrease chances of needlestick injuries. For instance, the WHO recommended the use of safety syringes with sharp injury protection (SIP), in order to prevent needlestick injuries. Moreover, in May 2017, Innovative Neurons LLC announced to commercialize its patented auto retractable multi-needle syringe known as FAST (fast, accessible, safe, and technology) to decrease needlestick injuries.
Major players operating in the global subcutaneous drug delivery market include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and Merck & Co., Inc.